This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Key Takeaways Insmed shares rose ~6% after Arikayce met primary and secondary goals in a phase IIIb MAC lung study.INSM plans regulatory filings in the United States and Japan to expand use to newly diagnosed patients.Arikayce's market could grow from ~30K to 200K patients, supporting potential blockbuster sales.Shares of Insmed (INSM) gained nearly 6% on Monday after the company reported positive top-line results from the phase IIIb ENCORE study evaluating Arikayce for label expansion in mycobacterium aviu ...

PresentationThank you for standing by, and welcome to the Insmed's Phase IIIb ENCORE study of ARIKAYCE in patients with newly diagnosed MAC lung infection not yet treated with antibiotics conference call. [Operator Instructions] I'd now like to turn the call over to Bryan Dunn, Head of Investor Relations. You may begin.Bryan DunnVice President of Investor Relations Thank you, Rob. Good day, everyone, and welcome to today's conference call to discuss the top line results of the Phase III ENCORE study of ARIK ...

Symptom Score Gains And Durable Culture ConversionThe ENCORE study’s results indicate that Arikayce (amikacin liposome inhalation suspension), in combination with a multidrug therapy, met its primary and all secondary endpoints, showcasing its potential to benefit patients with Mycobacterium avium complex lung infections.MAC lung infection is a chronic, often indolent respiratory illness caused by environmental bacteria (soil/water).The study met primary and all multiplicity-controlled secondary culture con ...

Helion Energy working on a massive fusion power deal with OpenAI We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience, personalize advertisements, and analyze website traffic. For these reasons, we may share your site usage data with our social media, advertising, and analytics partners. By clicking "Accept,†you agree to our website's cookie use as described in our Cookie Policy. You can change your cookie settings at any time by ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Summary of Insmed Phase IIIb ENCORE Study Conference Call Company and Industry - **Company**: Insmed - **Industry**: Pharmaceutical, specifically focusing on treatments for MAC (Mycobacterium avium complex) lung infections Core Points and Arguments 1. **Study Success**: The ENCORE trial demonstrated a statistically significant improvement in respiratory symptom scores for patients treated with ARIKAYCE compared to the placebo group, indicating its effectiveness in treating MAC lung infections [4][10] 2. **Culture Conversion**: The study showed that 82.4% of patients in the ARIKAYCE arm achieved culture conversion by month 13, compared to 55.6% in the control arm, with a highly significant difference of approximately 27 percentage points [14][15] 3. **Durability of Treatment**: The results indicated that the benefits of ARIKAYCE persisted even after treatment cessation, with 76.2% of patients maintaining culture conversion at month 15 [16][17] 4. **Regulatory Submissions**: Insmed plans to pursue regulatory submissions with the FDA and PMDA in the second half of the year, aiming to expand the label to include all patients with MAC lung infections, increasing the addressable patient population from around 30,000 to over 200,000 [6][22] 5. **Safety Profile**: The safety profile of ARIKAYCE was consistent with previous studies, with no new safety signals observed. The treatment discontinuation rate was 18.3%, lower than previous studies, indicating improved tolerability [20][21] 6. **Patient-Reported Outcomes**: The study utilized a validated patient-reported outcome tool, which is a first in this disease state, enhancing the credibility of the findings [5][9] 7. **Market Potential**: The expansion of the patient population and the positive results from the study are expected to lead to significant revenue growth, with potential market penetration anticipated in the next 12-24 months [57][76] Other Important Content 1. **Comparison to Standard of Care**: The study aimed to establish a new standard of care by demonstrating that ARIKAYCE, when added to a two-drug regimen, provides significant benefits in both symptoms and culture conversion [25][26] 2. **Long-term Benefits**: While the study did not specifically assess survival benefits, the durable culture conversion suggests potential long-term advantages for patients, including reduced risk of becoming refractory to treatment [29][31] 3. **Dysphonia Rates**: Dysphonia was reported in 50.7% of patients in the ARIKAYCE arm, but measures to mitigate this side effect have been identified, enhancing the overall benefit-risk profile [36][37] 4. **Real-World Applicability**: The trial population is considered representative of real-world treatment practices, which may facilitate the adoption of ARIKAYCE in clinical settings [42][43] 5. **International Market**: Japan is highlighted as a significant market opportunity due to a higher prevalence of MAC infections, with expectations for continued revenue generation from this region [72][73] This summary encapsulates the key findings and implications from the conference call regarding the ENCORE study and the future of ARIKAYCE in treating MAC lung infections.

Insmed Incorporated (INSM) on Monday reported positive topline results from the Phase 3b ENCORE study evaluating ARIKAYCE in patients with a new occurrence of Mycobacterium avium complex (MAC) lung infection who had not previously received antibiotics. Shares rose more than 10% in pre-market trading.The ENCORE trial assessed once-daily ARIKAYCE plus multidrug therapy versus placebo plus multidrug therapy over 12 months. Among participants, 82.4% were experiencing their first MAC infection, while 17.6% had ...

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease Accessibility StatementSkip Navigation —The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom Score and Culture Conversion Rates— —In the Second Half of 2026, Insmed Plans to File a Supplemental NDA for ARIKAYCE ...

Group 1 - Artisan Small Cap Fund aims to invest in companies with franchise characteristics, strong earnings trajectories, and trading at a discount to estimated private market value [1] - In Q4 2025, the Fund posted strong absolute returns, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index, despite elevated volatility and shifting market sentiment [1] - For the full year 2025, the Fund generated strong results but underperformed compared to both indexes [1] Group 2 - Insmed Incorporated (NASDAQ:INSM) was highlighted as a leading contributor in Q4 2025, focusing on therapies for serious and rare diseases [2][3] - As of March 16, 2026, Insmed's stock closed at $144.60 per share, with a one-month return of -3.93% and a 52-week gain of 87.82% [2] - Insmed's market capitalization is reported at $31.17 billion [2] - The company launched Brinsupri™ (brensocatib), generating $28 million in initial sales from approximately 2,500 patients and 1,700 prescribers, contributing to its strong performance [3]